Cytek Biosciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cytek Biosciences (NASDAQ:CTKB) Full Year 2024 Results

Key Financial Results

• Revenue: US$200.5m (up 3.9% from FY 2023).
• Net loss: US$6.02m (loss narrowed by 50% from FY 2023).
• US$0.046 loss per share (improved from US$0.09 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cytek Biosciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 12% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Cytek Biosciences' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.